<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 10-Q

 /x/ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For Quarter Ended March 31,2000
                                       OR

/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
     SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________________  to _________________

                          Commission File Number 0-6516

                                 DATASCOPE CORP.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

Delaware                                             13-2529596
--------------------------------------------------------------------------------
(State of other jurisdiction of                      (I.R.S. Employer
incorporation or organization)                       Identification No.)

               14 Philips Parkway, Montvale, New Jersey 07645-9998
--------------------------------------------------------------------------------
                    (Address of principal executive offices)

                                 (201) 391-8100
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

Former name, former address and former fiscal year, if changed since last
report:

     Indicate by check mark whether the registrant
     (1) has filed all reports required to be filed by Section 13 or 15 (d) of
         the Securities Exchange Act of 1934 during the preceding 12 months (or
         for such shorter period that the registrant was required to file such
         reports), and

     (2) has been subject to such filing requirements for the past 90 days.
                YES     X          NO
                       ---            ---

Number of Shares of Company's Common Stock outstanding as of April 28, 2000:
14,848,767.


<PAGE>


                        Datascope Corp. and Subsidiaries
                     Management's Discussion and Analysis of
                  Results of Operations and Financial Condition

Results of Operations

     The following is a comparison of the third quarter and first nine months of
     fiscal 2000 with the third quarter and first nine months of fiscal 1999.

     Net Sales

         Net sales of $77.6 million in the third quarter and $215.9 million in
         the first nine months of fiscal 2000 increased 10% and 12%,
         respectively.

         Sales of the Cardiac Assist / Monitoring Products segment increased 8%
         to $57.0 million in the third quarter and 8% to $160.1 million in the
         first nine months of fiscal 2000.

              Sales of cardiac assist products increased 4% to $30.0 million in
              the third quarter despite a comparison to record third quarter
              sales last year which resulted from the contribution of newly
              introduced products: the Profile 8 Fr. intra-aortic balloon
              catheter and the System 98 balloon pump. Worldwide market
              acceptance of both of these products continued strong. Sales in
              the first nine months of fiscal 2000 increased 6% to $84.5 million
              due to increased sales of the new products.

              Sales of patient monitoring products increased 12% to $27.0
              million in the third quarter and 9% to $75.6 million in the first
              nine months of fiscal 2000. The increased sales resulted primarily
              from higher shipments of the Passport portable monitor, the new
              Accutorr(R) Plus blood pressure monitor as well as strong
              international shipments of the Company's new Passport 2(TM)
              portable bedside monitor, which was introduced in international
              markets last quarter. During the third quarter, we received FDA
              510(k) clearance to market the new Passport 2. The new monitor
              line began shipping in the U.S. in late March and is generating
              strong demand.

         Sales of the Collagen Products / Vascular Grafts segment increased 18%
         to $20.6 million in the third quarter and 27% to $55.8 million in the
         first nine months of fiscal 2000.

              Sales of VasoSeal(R) arterial puncture sealing devices increased
              30% to a record $15.0 million in the third quarter and 37% to
              $40.3 million in the first nine months of fiscal 2000. VasoSeal's
              strong sales growth reflects continued market growth, higher
              average selling prices and increased sales force productivity.
              VasoSeal ES, the Company's second generation product,


<PAGE>

              which was introduced worldwide in the first quarter continued to
              grow strongly. During the third quarter, VasoSeal ES sales
              exceeded 20% of worldwide VasoSeal arterial puncture sealing
              device sales.

              International sales of InterVascular Inc., which account for close
              to 90% of its total sales, increased 19% to $4.8 million in the
              third quarter of fiscal 2000 due to continued strong demand for
              new products, particularly the InterGard(R) Silver, the world's
              first anti-microbial vascular graft. Domestic sales declined
              sharply reflecting an inventory reduction by the Company's U.S.
              distributor. As a result, worldwide sales of InterVascular in the
              third quarter were 4% less than last year at $5.4 million. For the
              first nine months of fiscal 2000 sales increased 6% to $14.9
              million, attributable primarily to increased international
              shipments of new products.

         The stronger U.S. dollar compared to major European currencies
         decreased total sales by approximately $1.1 million in the third
         quarter and $2.5 million in the first nine months of fiscal 2000.

     Gross Profit (Net Sales Less Cost of Sales)

         The gross profit percentage was 61.4% for the third quarter and 61.6%
         for the first nine months of fiscal 2000, compared to 61.4% for both
         the third quarter and first nine months last year. The gross profit
         percentage in the third quarter and first nine months of fiscal 2000
         benefitted from increased sales of higher margin products, offset by
         lower average selling prices for certain patient monitoring products.

     Research and Development (R&D)

         R&D expenses, as a percentage of sales, were 8.9% for the third quarter
         and 9.1% for the first nine months of fiscal 2000, compared to 10.4%
         and 11.7% for the corresponding periods last year.

         R&D expenses were $6.9 million in the third quarter and $19.7 million
         for the first nine months of fiscal 2000 compared to $7.4 million and
         $22.6 million for the corresponding periods last year. The decrease was
         primarily due to cost savings from the restructuring program
         implemented in the second half of last year and reduced development
         expenses in the Patient Monitoring product line.

     Selling, General & Administrative Expenses (SG&A)

         SG&A expenses, as a percentage of sales, were 38.7% in the third
         quarter and 40.1% in the first nine months of fiscal 2000, compared to
         38.6% and 39.7% in the corresponding periods last year.


<PAGE>



         SG&A expenses increased $2.8 million or 10% in the third quarter and
         $10.0 million or 13% in the first nine months of fiscal 2000 primarily
         as a result of increased corporate expenses and higher selling expenses
         in the VasoSeal product line, resulting from the sales force expansion.

         The stronger U.S. dollar compared to major European currencies
         decreased SG&A expenses by approximately $0.7 million in the third
         quarter and $1.6 million in the first nine months of fiscal 2000.

     Restructuring Charge - Third Quarter Fiscal 1999

         During the third quarter of fiscal 1999 we recorded a pretax
         restructuring charge of $864 thousand, equivalent to $605 thousand
         after tax or $0.04 per diluted share. Based on a review by senior
         management of all company operations in the first half of fiscal 1999,
         a restructuring plan was approved to reduce our cost structure and
         streamline certain operations. The restructuring plan resulted in a
         workforce reduction of approximately 40 employees in certain
         administrative, R&D and manufacturing functions. The annual cost
         savings for the workforce reduction is approximately $2.5 million. The
         workforce reduction did not have any significant impact on our
         operations.

     Interest Income and Expense

         Interest income in the third quarter of $0.9 million increased $0.2
         million or 29% compared to the third quarter last year. The increased
         interest income in the third quarter of fiscal 2000 was attributable to
         a 17% increase in the average investment portfolio from $56.9 million
         to $66.7 million and an increase in the average yield to 5.6% from
         5.1%. Interest income of $2.6 million for the first nine months of
         fiscal 2000 increased 3% compared to the same period last year, in line
         with a 3% increase in the average investment portfolio.

     Income Taxes

         The consolidated effective tax rate was 32.0% for the third quarter and
         31.5% for the first nine months of fiscal 2000 compared to 29.0% and
         30.2% for the corresponding periods last year. The higher tax rate in
         the fiscal 2000 periods was due mainly to the expiration of a tax
         exemption in an industrial development zone in Europe on December 31,
         1999.


<PAGE>


     Net Earnings

         Net earnings were $10.5 million or $0.66 per diluted share in the third
         quarter and $22.7 million or $1.42 per diluted share in the first nine
         months of fiscal 2000 compared to $6.0 million, or $0.38 per diluted
         share and $14.5 million or $0.93 per diluted share for the
         corresponding periods last year.

         Net earnings in the third quarter and first nine month periods of
         fiscal 2000 and 1999 included the following special items:

         Third Quarter Fiscal 2000
         o    gain on sale of technology of $2.5 million after tax or $0.16 per
              diluted share.
         Third Quarter Fiscal 1999
         o    restructuring charge of $605 thousand after tax or $.04 per
              diluted share related to a workforce reduction program.

         Excluding special items, net earnings were $8.0 million or $0.50 per
         diluted share in the third quarter and $20.2 million or $1.26 per
         diluted share in the first nine months of fiscal 2000, compared to $6.6
         million or $0.42 per diluted share and $15.1 million or $0.97 per
         diluted share for the corresponding periods last year. The increased
         earnings reflect:
         o    sales growth
         o    a more profitable product mix
         o    cost savings from the restructuring program implemented in the
              second half of fiscal 1999

     Liquidity and Capital Resources

         Working capital was $115.9 million at March 31, 2000, compared to
         $125.4 million at June 30, 1999 and the current ratio was 3.5:1
         compared to 4.0:1. The lower working capital and current ratio were
         impacted primarily by a decline in cash and short term investments
         attributable to the stock repurchase programs and construction of the
         Mahwah, New Jersey facility, and an increase in accrued expenses
         related to higher sales.

         In the first nine months of fiscal 2000 cash provided by operations was
         $29.8 million, compared to a cash use of $5.2 million last year. The
         $35.0 million improvement is primarily attributable to higher net
         earnings, depreciation and amortization, and lower accounts receivable,
         partially offset by increased inventories to support new product
         introductions. Net cash used in investing activities was $12.3 million,
         primarily attributable to the purchase of $13.4 million of property,
         plant and equipment and a $2.5 million equity investment in AMG, and an
         allied company (see "Equity Investment" section below). Net cash used
         in financing activities was $19.7 million, attributable to stock
         repurchases of $21.7 million and $1.2 million dividends paid, partially
         offset by $3.2 million cash received from exercise of stock options.

         On September 14, 1999 we announced a program to buy $30 million of our
         common stock. Through March 31, 2000 we expended $12.7 million to
         purchase about 386


<PAGE>

         thousand shares of our common stock under this program. In September
         1999, we completed our second stock repurchase program to buy $20
         million of our common stock.

         On February 17, 2000, the Board of Directors declared a quarterly cash
         dividend of $0.04 per share payable on March 30, 2000 to stockholders
         of record at March 2, 2000.

         We believe our financial resources are sufficient to meet our projected
         cash requirements.

         The moderate rate of current U.S. inflation has not significantly
         affected the Company.

     Year 2000

         Starting in fiscal 1998 we commenced a program to identify, remediate,
         test and develop contingency plans for the Year 2000 issue in our
         computer information systems, products, vendors, suppliers and
         customers.

         As of May 12, 2000, we had not experienced any Year 2000 problems
         regarding our computer information systems (CIS), products, vendors,
         suppliers or customers that caused disruptions in any of our business
         operations.

         The cost to modify the computer software programs used in our CIS was
         covered by existing service agreements with the software vendors. The
         assessments, testing and verification of our CIS products was performed
         by existing staff and no significant outside resources were required.
         Despite the use of internal resources for the Year 2000 Program, there
         was no significant deferral of other CIS projects. We do not anticipate
         that any remaining cost for the Year 2000 Program will be material to
         our financial condition or results of operations.

     Equity Investment

         During the third quarter fiscal 2000 we purchased a 30% equity interest
         in AMG GmbH, a private German distributor of proprietary stent
         products, and in an allied development and manufacturing company. The
         cost of the purchase was $2.5 million, including $0.3 million of
         related expenses. The purchase agreement for AMG and the allied company
         includes an option to acquire the remaining 70% of the companies at an
         established price within two years. The investment was modestly
         accretive in the third quarter.

     Euro Conversion

         As part of the European Economic and Monetary Union (EMU), a single
         currency (Euro) will replace the national currencies of most of the
         European countries in which we conduct our business. The conversion
         rates between the Euro and the participating nations' currencies have
         been fixed irrevocably as of January 1, 1999. During a transition
         period from January 1, 1999 to December 31, 2001 parties may settle
         transactions using either Euro or the participating country's national
         currency. The participating national currencies will be removed from
         circulation between January 1, 2002 and June 30, 2002 and replaced by
         Euro notes and coinage. Full conversion of all affected country
         operations to


<PAGE>

         the Euro currency is expected to be completed by the time national
         currencies are removed from circulation.

         We are currently involved in the phased conversion to the Euro and the
         effects on revenues, costs and various business strategies are being
         assessed. We are able to conduct business in both the Euro and national
         currencies on an as needed basis, as required by the European Union.
         The cost of software and business process conversion is not expected to
         be material to our financial condition or results of operations.

     Information Concerning Forward Looking Statements

         This Management's Discussion and Analysis of Results of Operations and
         Financial Condition includes forward-looking statements that involve
         risks and uncertainties because of the possibility that market
         conditions may change, particularly as the result of competitive
         activity in the cardiac assist and other markets served by the Company,
         the Company's ability to gain market acceptance for new products and
         the Company's dependence on certain suppliers for patient monitoring
         and VasoSeal products. Additional risks are the ability of the Company
         to successfully introduce new products, continued demand for the
         Company's products generally, the rapid and significant changes that
         characterize the medical device industry and the ability to continue to
         respond to such technological changes, the uncertain timing of
         regulatory approvals, as well as other risks detailed from time to time
         in documents filed by Datascope with the Securities and Exchange
         Commission.

     Quantitative and Qualitative Disclosures About Market Risk

         Due to the global nature of our operations, we are subject to the
         exposures that arise from foreign exchange rate fluctuations. Our
         objective in managing the exposure to foreign currency fluctuations is
         to minimize net earnings volatility associated with foreign exchange
         rate changes. We enter into foreign currency forward exchange contracts
         to hedge a substantial portion of the foreign currency transactions
         which are primarily related to certain intercompany receivables
         denominated in foreign currencies. Our hedging activities do not
         subject us to exchange rate risk because gains and losses on these
         contracts offset losses and gains on the assets, liabilities and
         transactions being hedged.

         We do not use derivative financial instruments for trading purposes.
         None of our foreign currency forward exchange contracts are designated
         as economic hedges of our net investment in foreign subsidiaries.

         As of March 31, 2000, we had $4.8 million of foreign exchange forward
         contracts outstanding, all of which were in European currencies. The
         foreign exchange forward contracts generally have maturities that do
         not exceed 12 months and require us to exchange foreign currencies for
         U.S. dollars at maturity, at rates agreed to when the contract is
         signed.


<PAGE>

                        Datascope Corp. and Subsidiaries
                           Consolidated Balance Sheets
                                 (In thousands)

<TABLE>
<CAPTION>
                                                                       March 31,             June 30,
                                                                          2000                 1999
                                                                     ---------------      ---------------
<S>                                                                  <C>                  <C>
Assets                                                                (unaudited)                (a)
Current Assets:
  Cash and cash equivalents                                          $        2,851        $       4,572
  Short-term investments                                                     43,600               45,539
  Accounts receivable less allowance for
    doubtful accounts of $1,315 and $1,192                                   63,136               64,289
  Inventories                                                                43,888               42,747
  Prepaid expenses and other current assets                                   9,790                9,439
                                                                     ---------------      ---------------
      Total Current Assets                                                  163,265              166,586

Property, Plant and Equipment, net of accumulated
    depreciation of $58,390 and $53,353                                      72,739               63,321
Non-Current Marketable Securities                                            18,914               20,496
Other Assets                                                                 23,347               19,091
                                                                     ---------------      ---------------
                                                                      $     278,265        $     269,494
                                                                     ===============      ===============

Liabilities and Stockholders' Equity
Current Liabilities:
  Accounts payable                                                   $        9,782        $      10,565
  Accrued expenses                                                           14,433               10,721
  Accrued compensation                                                       15,455               13,804
  Deferred revenue                                                            4,364                4,380
  Taxes on income                                                             3,286                1,695
                                                                     ---------------      ---------------
      Total Current Liabilities                                              47,320               41,165

Other Liabilities                                                            14,089               13,874
Stockholders' Equity
  Preferred stock, par value $1.00 per share:
    Authorized 5 million shares; Issued, none                                    --                   --
  Common stock, par value $.01 per share:
    Authorized, 45 million shares; Issued and
    outstanding, 16,921 and 16,663 shares                                       169                  167
  Additional paid-in capital                                                 56,528               52,570
  Treasury stock at cost, 2,083 and 1,416 shares                            (52,740)             (31,079)
  Retained earnings                                                         220,413              198,921
  Accumulated other comprehensive income                                     (7,514)              (6,124)
                                                                     ---------------      ---------------
                                                                            216,856              214,455
                                                                     ---------------      ---------------
                                                                      $     278,265        $     269,494
                                                                     ===============      ===============
</TABLE>


                  (a) Derived from audited financial statements
                 See notes to consolidated financial statements


<PAGE>

                        Datascope Corp. and Subsidiaries
                       Statements of Consolidated Earnings
                    (In thousands, except per share amounts)

                                   (Unaudited)

<TABLE>
<CAPTION>
                                                           Nine Months Ended                   Three Months Ended
                                                               March 31,                           March 31,
                                                   ----------------------------------      --------------------------------
                                                        2000              1999                  2000              1999
                                                   ----------------   ----------------     --------------    --------------
<S>                                                <C>                <C>                  <C>               <C>
Net Sales                                          $       215,900    $       192,900      $      77,600     $      70,500
                                                   ----------------   ----------------     --------------    --------------
Costs and Expenses:
  Cost of sales                                             82,885             74,443             29,978            27,197
  Research and development
    expenses                                                19,650             22,618              6,870             7,355
  Selling, general and
    administrative expenses                                 86,601             76,555             30,008            27,248
  Gain on sale of technology                                (3,825)                --             (3,825)               --
  Restructuring charges                                         --                864                 --               864
                                                   ----------------   ----------------     --------------    --------------
                                                           185,311            174,480             63,031            62,664
                                                   ----------------   ----------------     --------------    --------------
Operating Earnings                                          30,589             18,420             14,569             7,836
Other (Income) Expense:
  Interest income                                           (2,661)            (2,602)              (939)             (733)
  Interest expense                                              15                 27                  5                 7
  Other, net                                                   110                176                 60               159
                                                   ----------------   ----------------     --------------    --------------
                                                            (2,536)            (2,399)              (874)             (567)
                                                   ----------------   ----------------     --------------    --------------
Earnings Before Taxes on Income                             33,125             20,819             15,443             8,403
Taxes on Income                                             10,429              6,286              4,948             2,437
                                                   ----------------   ----------------     --------------    --------------
Net Earnings                                       $        22,696    $        14,533      $      10,495     $       5,966
                                                   ================   ================     ==============    ==============

Earnings Per Share, Basic                          $          1.50    $          0.95      $        0.70     $        0.39
                                                   ================   ================     ==============    ==============
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Basic                                 15,084             15,254             15,050            15,181
                                                   ================   ================     ==============    ==============

Earnings Per Share, Diluted                        $          1.42    $          0.93        $      0.66     $        0.38
                                                   ================   ================     ==============    ==============
Weighted Average Number of
  Common and Common Equivalent
  Shares Outstanding, Diluted                               16,022             15,684             15,989            15,662
                                                   ================   ================     ==============    ==============
</TABLE>



                 See notes to consolidated financial statements

<PAGE>

                        Datascope Corp. and Subsidiaries
                      Statements of Consolidated Cash Flows
                             (Dollars in thousands)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                          Nine Months Ended
                                                                                               March 31,
                                                                                -----------------------------------
                                                                                      2000                1999
                                                                                ----------------      -------------
<S>                                                                             <C>                   <C>
Operating Activities:
      Net cash provided by (used in) operating activities                       $        29,940       $     (5,156)
                                                                                ----------------      -------------

Investing Activities:
      Capital expenditures                                                              (13,373)           (10,580)
      Purchases of marketable securities                                                (66,970)           (23,856)
      Maturities of marketable securities                                                70,490             51,875
      AMG equity investment                                                              (2,525)                --
      Acquisition of Polyprobe, Inc. and Alpha Probe, Inc.                                   --               (450)
                                                                                ----------------      -------------
      Net cash (used in) provided by investing activities                               (12,378)            16,989
                                                                                ----------------      -------------

Financing Activities:
      Treasury shares acquired under repurchase programs                                (21,661)           (12,893)
      Exercise of stock options and other                                                 3,197              1,526
      Cash dividends paid                                                                (1,204)                --
                                                                                ----------------      -------------
      Net cash used in financing activities                                             (19,668)           (11,367)
                                                                                ----------------      -------------

      Effect of exchange rates on cash                                                      385                145
                                                                                ----------------      -------------

(Decrease) increase in cash and cash equivalents                                         (1,721)               611
Cash and cash equivalents, beginning of period                                            4,572              3,364
                                                                                ----------------      -------------

Cash and cash equivalents, end of period                                        $         2,851       $      3,975
                                                                                ================      =============

Supplemental Cash Flow Information
      Cash Paid during the period for:
        Income taxes                                                            $         7,803       $      4,899
                                                                                ----------------      -------------

      Non-cash transactions:
        Net transfers of inventory to fixed assets
          for use as demonstration equipment                                    $         5,794       $      6,131
                                                                                ----------------      -------------

      Issuance of common stock for acquisition
           of Polyprobe, Inc. and Alpha Probe, Inc.                             $            --       $      2,700
                                                                                ----------------      -------------

</TABLE>

                 See notes to consolidated financial statements



<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

1.  Basis of Presentation

The consolidated financial statements include the accounts of Datascope Corp.
and its subsidiaries (the "Company" - which may be referred to as "our", "us" or
"we").

The consolidated balance sheet as of March 31, 2000, the statements of
consolidated earnings for the three and nine month periods ended March 31, 2000
and 1999 and the statements of cash flows for the nine month periods ended March
31, 2000 and 1999 have been prepared by the Company, without audit. In our
opinion, all adjustments (which include only normal recurring adjustments) have
been made that are necessary to present fairly the financial position, results
of operations and cash flows for all periods presented.

Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. We recommend that you read these condensed
consolidated financial statements in conjunction with the financial statements
and notes included in our Annual Report on Form 10-K for the fiscal year ended
June 30, 1999. The results of operations for the period ended March 31, 2000 are
not necessarily indicative of a full year's operations.

We have reclassified certain prior year information to conform with the current
year presentation.

2.  Inventories

Inventories are stated at the lower of cost or market, with cost determined on a
first-in, first-out basis.

                               ------------         ------------
                                 March 31,            June 30,
                                   2000                 1999
                               ------------         ------------
         Materials                 $15,182              $15,788
         Work in Process             5,550                6,229
         Finished Goods             23,156               20,730
                               ------------         ------------
                                   $43,888              $42,747
                               ============         ============

3.  Stockholders' Equity

Changes in the components of stockholders' equity for the nine months ended
March 31, 2000 were as follows:

           Net income                                          $22,696
           Foreign currency translation adjustments             (1,390)
           Common stock and additional paid-in
              capital effects of stock option activity           3,960
           Cash dividends on common stock                       (1,204)
           Purchases under stock repurchase plans              (21,661)
                                                           ------------
           Total increase in stockholders' equity               $2,401
                                                           ============



<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

4.  Earnings Per Share

In accordance with Financial Accounting Standard No. 128, "Earnings Per Share",
we disclose both Basic and Diluted Earnings Per Share. The reconciliation of
Basic Earnings Per Share to Diluted Earnings Per Share is as follows:

<TABLE>
<CAPTION>
---------------------------------      ----------------------------------------       -------------------------------------
For Three Months Ended                             March 31, 2000                               March 31, 1999
---------------------------------      -----------------------------------------      -------------------------------------
                                           Net                     Per Share              Net                    Per Share
Basic EPS                               Earnings       Shares        Amount            Earnings       Shares      Amount
---------                              ------------  ------------  ------------       ------------  ----------- -----------
<S>                                    <C>           <C>            <C>               <C>           <C>          <C>
Earnings available to
   common shareholders                     $10,495        15,050         $0.70             $5,966       15,181       $0.39

Diluted EPS
-----------
Options issued to employees                     --           939         (0.04)                --          481       (0.01)
                                       ------------  ------------  ------------       ------------  ----------- -----------

Earnings available to
   common shareholders
   plus assumed conversions                $10,495        15,989         $0.66             $5,966       15,662       $0.38
                                       ============  ============  ============       ============  =========== ===========

<CAPTION>
---------------------------------      ----------------------------------------       -------------------------------------
For Nine Months Ended                              March 31, 2000                               March 31, 1999
---------------------------------      -----------------------------------------      -------------------------------------
                                           Net                     Per Share              Net                    Per Share
Basic EPS                               Earnings       Shares        Amount            Earnings       Shares      Amount
---------                              ------------  ------------  ------------       ------------  ----------- -----------
<S>                                    <C>           <C>            <C>               <C>           <C>          <C>
Earnings available to
   common shareholders                     $22,696        15,084         $1.50            $14,533       15,254       $0.95

Diluted EPS
-----------
Options issued to employees                     --           938         (0.08)                --          430       (0.02)
                                       ------------  ------------  ------------       ------------  ----------- -----------

Earnings available to
   common shareholders
   plus assumed conversions                $22,696        16,022         $1.42            $14,533       15,684       $0.93
                                       ============  ============  ============       ============  =========== ===========
</TABLE>

5.  Comprehensive Income

In accordance with Financial Accounting Standard No. 130, "Reporting
Comprehensive Income", we disclose comprehensive income and its components. For
the three and nine month periods ended March 31, 2000 and 1999 our comprehensive
income was as follows:

<TABLE>
<CAPTION>
                                                         Nine Months Ended               Three Months Ended
                                                     --------------------------       -------------------------
                                                       3/31/00       3/31/99            3/31/00      3/31/99
                                                     ------------  ------------       ------------  -----------
<S>                                                  <C>           <C>                <C>           <C>
           Net earnings                                  $22,696       $14,533            $10,495       $5,966
           Foreign currency translation
              gain or (loss)                              (1,390)         (156)              (974)      (1,536)
                                                     ------------  ------------       ------------  -----------
           Total comprehensive income                    $21,306       $14,377             $9,521       $4,430
                                                     ============  ============       ============  ===========

</TABLE>

<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

6.  Segment Information

Our business is the development, manufacture and sale of medical devices. We
have two reportable segments, Cardiac Assist/Monitoring Products and Collagen
Products/Vascular Grafts.

The Cardiac Assist/Monitoring Products segment includes electronic intra-aortic
balloon pumps and catheters that are used in the treatment of vascular disease
and electronic physiological monitors that provide for patient safety and
management of patient care.

The Collagen Products/Vascular Grafts segment includes extravascular
hemostasis devices which are used to seal arterial puncture wounds to stop
bleeding after cardiovascular catheterization procedures and a proprietary line
of knitted and woven vascular grafts and patches for reconstructive vascular and
cardiovascular surgery.

We have aggregated our product lines into two segments based on similar
manufacturing processes, distribution channels, regulatory environments and
customers. Management evaluates the revenue and profitability performance of
each of our product lines to make operating and strategic decisions. We have no
intersegment revenue. Net sales and operating margin are shown below.

<TABLE>
<CAPTION>
                                                           Cardiac       Collagen
                                                          Assist /      Products /        Corporate
                                                         Monitoring      Vascular            and
                                                          Products        Grafts            Other         Consolidated
                                                        --------------  --------------  ---------------- ----------------
<S>                                                     <C>             <C>             <C>               <C>
Three months ended March 31, 2000
-----------------------------------------
Net sales to external customers                               $56,976         $20,624                --          $77,600
                                                        -----------------------------------------------------------------
Operating margin                                               $7,483          $5,538           ($2,277)         $10,744
                                                        -----------------------------------------------------------------

Three months ended March 31, 1999
-----------------------------------------
Net sales to external customers                               $52,961         $17,539                --          $70,500
                                                        -----------------------------------------------------------------
Operating margin                                               $7,135          $2,542             ($977)          $8,700
                                                        -----------------------------------------------------------------

Nine months ended March 31, 2000
-----------------------------------------
Net sales to external customers                              $160,137         $55,763                --         $215,900
                                                        -----------------------------------------------------------------
Operating margin                                              $18,350         $11,704           ($3,290)         $26,764
                                                        -----------------------------------------------------------------

Nine months ended March 31, 1999
-----------------------------------------
Net sales to external customers                              $148,958         $43,942                --         $192,900
                                                        -----------------------------------------------------------------
Operating margin                                              $18,153          $3,680           ($2,549)         $19,284
                                                        -----------------------------------------------------------------

<CAPTION>
                                                                Nine Months Ended                 Three Months Ended
Reconciliation to consolidated earnings                 ------------------------------  ---------------------------------
    before income taxes :                                     3/31/00         3/31/99           3/31/00          3/31/99
-----------------------------------------               --------------  --------------  ---------------- ----------------
<S>                                                     <C>             <C>             <C>               <C>
Consolidated operating margin                                 $26,764         $19,284           $10,744           $8,700
Interest income, net                                            2,646           2,575               934              726
Other (expense) income                                           (110)           (176)              (60)            (159)
Special items ( a )                                             3,825            (864)            3,825             (864)
                                                        --------------  --------------  ---------------- ----------------
Consolidated earnings before taxes                            $33,125         $20,819           $15,443           $8,403
                                                        ==============  ==============  ================ ================
</TABLE>

( a ) Gain on sale of technology in FY 2000 and restructuring costs in FY 1999.


<PAGE>

                        Datascope Corp. and Subsidiaries
                   Notes to Consolidated Financial Statements
                 (Unaudited, in thousands except per share data)

7.  Restructuring Program

Based upon a review by senior management of all company operations, a
restructuring plan was approved in fiscal year 1999 to reduce the company's cost
structure and streamline certain operations. We recorded pre-tax restructuring
charges totaling $3.43 million, or $0.14 per share, during the second half of
fiscal 1999 related to the following cost reduction initiatives:

   o     Closure of InterVascular's Clearwater, Florida leased manufacturing
         facility in order to reduce costs and centralize operations in our
         expanded manufacturing facility in LaCiotat, France.

   o     Workforce reductions in certain administrative, R&D and manufacturing
         positions throughout the company.

   o     Writedown of certain Genisphere fixed assets based on the revised
         market entry strategy for the proprietary 3DNA technology. Under the
         revised market entry stategy we will focus product development on
         improving the performance of newly-developing technologies for drug
         discovery used by the pharmaceutical and biotech industries.

A summary of the restructuring charges and remaining liability at March 31, 2000
is shown below.

<TABLE>
<CAPTION>
                                             Clearwater                     Genisphere
                                                Plant        Employee          Asset
                                               Closure       Severance       Writedown         Total
                                            --------------  --------------  -------------- ---------------
<S>                                         <C>             <C>             <C>            <C>
Fiscal 1999 restructuring charges                $880          $1,674            $875          $3,429
Utilized through March 31, 2000                   633           1,220             875           2,728
                                            --------------  --------------  -------------- ---------------
Remaining liability at March 31, 2000            $247            $454              --            $701
                                            ==============  ==============  ============== ===============
</TABLE>

The remaining liability is for severance payments for employees who will be
leaving over the next six months. No significant additional expenditures are
anticipated to complete the restructuring program.


<PAGE>



Part II:

Item 6.  Exhibits and Reports on Form 8-K

              a.  Exhibits

                  none

              b.  Reports on Form 8-K. No reports on Form 8-K have been filed
                  during the quarter for which this report is filed.


<PAGE>



                                                                       Form 10-Q

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned, thereunto duly authorized.




                                            DATASCOPE CORP.
                                            Registrant









                                       By: \s\ Lawrence Saper
                                           ------------------------------
                                           Chairman of the Board and
                                           Chief Executive Officer







                                       By: \s\ Leonard S. Goodman
                                           ------------------------------
                                           Vice President, CFO and Treasurer

Dated:  May 5, 2000